You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 14, 2025

CLINICAL TRIALS PROFILE FOR COMPAZINE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Compazine

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000654 ↗ The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU Completed Oclassen Pharmaceuticals Phase 2 1969-12-31 To determine the tolerance of HIV-infected patients to TID oral doses of FIAU syrup at 4 different dose levels. To determine the peak and trough blood levels of FIAU and its metabolites during two weeks of oral dosing with FIAU. The pyrimidine nucleoside analog FIAC and its primary deaminated uracil metabolite FIAU are highly and specifically active compounds in vitro against several herpes group viruses, particularly herpes simplex virus (HSV) types 1 and 2, varicella zoster (VZV), and cytomegalovirus (CMV), as well as hepatitis B virus (HBV). Since FIAU is the primary metabolite of FIAC and the administration of FIAU simplifies the metabolism of FIAC, it is anticipated from clinical studies of FIAC that FIAU will be tolerated at least as well as FIAC. A single-dose, pharmacokinetic (blood level) study showed that FIAC, when taken orally, is readily absorbed into the bloodstream, and most of it is converted to FIAU. Daily oral doses are expected to provide concentrations of FIAU exceeding the in vitro minimum inhibitory concentration for nearly all the herpes group viruses.
NCT00000654 ↗ The Tolerance of HIV-Infected Patients With Herpes Group Virus Infections to Oral Doses of FIAU Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 2 1969-12-31 To determine the tolerance of HIV-infected patients to TID oral doses of FIAU syrup at 4 different dose levels. To determine the peak and trough blood levels of FIAU and its metabolites during two weeks of oral dosing with FIAU. The pyrimidine nucleoside analog FIAC and its primary deaminated uracil metabolite FIAU are highly and specifically active compounds in vitro against several herpes group viruses, particularly herpes simplex virus (HSV) types 1 and 2, varicella zoster (VZV), and cytomegalovirus (CMV), as well as hepatitis B virus (HBV). Since FIAU is the primary metabolite of FIAC and the administration of FIAU simplifies the metabolism of FIAC, it is anticipated from clinical studies of FIAC that FIAU will be tolerated at least as well as FIAC. A single-dose, pharmacokinetic (blood level) study showed that FIAC, when taken orally, is readily absorbed into the bloodstream, and most of it is converted to FIAU. Daily oral doses are expected to provide concentrations of FIAU exceeding the in vitro minimum inhibitory concentration for nearly all the herpes group viruses.
NCT00146042 ↗ UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer Completed Genentech, Inc. Phase 2 1999-03-01 This is a research study which aims to improve the way that doctors determine the dose of chemotherapy given to patients. Right now, chemotherapy is determined by a patient's height and weight. However, some patients metabolize chemotherapy faster or slower than the average person because of a different level of drug metabolizing enzyme in the liver. Therefore, some patients are either given too small or too large a dose of chemotherapy because the amount of enzyme is not taken into account. This research study will examine the use of a simple test, call the Erythromycin Breath Test(ERMBT) to determine the amount of enzyme which can metabolize the chemotherapy drug docetaxel (Taxotere). The dose of docetaxel will be tailored to the amount of enzyme which is available to metabolize the drug for each patient. The drug, docetaxel, is combined with another drug, trastuzumab (Herceptin), because at this time this combination appears to be promising in metastatic breast cancer research.
NCT00146042 ↗ UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer Completed University of Michigan Cancer Center Phase 2 1999-03-01 This is a research study which aims to improve the way that doctors determine the dose of chemotherapy given to patients. Right now, chemotherapy is determined by a patient's height and weight. However, some patients metabolize chemotherapy faster or slower than the average person because of a different level of drug metabolizing enzyme in the liver. Therefore, some patients are either given too small or too large a dose of chemotherapy because the amount of enzyme is not taken into account. This research study will examine the use of a simple test, call the Erythromycin Breath Test(ERMBT) to determine the amount of enzyme which can metabolize the chemotherapy drug docetaxel (Taxotere). The dose of docetaxel will be tailored to the amount of enzyme which is available to metabolize the drug for each patient. The drug, docetaxel, is combined with another drug, trastuzumab (Herceptin), because at this time this combination appears to be promising in metastatic breast cancer research.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Compazine

Condition Name

Condition Name for Compazine
Intervention Trials
Headache 5
Migraine 2
Metastatic Breast Cancer 1
Glioblastoma 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Compazine
Intervention Trials
Headache 8
Migraine Disorders 5
Emergencies 3
Vomiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Compazine

Trials by Country

Trials by Country for Compazine
Location Trials
United States 35
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Compazine
Location Trials
Michigan 5
New York 4
Nevada 4
Pennsylvania 2
Ohio 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Compazine

Clinical Trial Phase

Clinical Trial Phase for Compazine
Clinical Trial Phase Trials
Phase 4 6
Phase 3 3
Phase 2/Phase 3 1
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Compazine
Clinical Trial Phase Trials
Completed 11
Unknown status 3
Withdrawn 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Compazine

Sponsor Name

Sponsor Name for Compazine
Sponsor Trials
University of Michigan Rogel Cancer Center 3
University of Michigan Cancer Center 2
University Medical Center of Southern Nevada 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Compazine
Sponsor Trials
Other 25
Industry 6
U.S. Fed 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials, Market Analysis, and Projections for Compazine

Introduction to Compazine

Compazine, also known as prochlorperazine, is a phenothiazine derivative used in the treatment of various conditions, including severe nausea and vomiting, schizophrenia, and generalized non-psychotic anxiety. Here, we will delve into the clinical trials, market analysis, and future projections for this drug.

Clinical Trials and Efficacy

Headache Treatment

One notable clinical trial involving Compazine was a prospective, randomized, double-blind study that evaluated its efficacy in treating severe headaches. The trial compared intravenous prochlorperazine edisylate with a placebo in 82 adult patients with vascular or tension-type headaches. The results showed that within 60 minutes, 74% of patients who received prochlorperazine experienced complete relief, and an additional 14% had partial relief, totaling 88% with either complete or partial relief. This was significantly higher than the 45% relief rate in the placebo group[1].

Anxiety and Other Indications

Compazine has also been studied for its effectiveness in treating generalized non-psychotic anxiety. Clinical studies have established its efficacy in this area, although it is not typically the first-line treatment due to associated risks such as tardive dyskinesia. The drug has been shown to be effective in short-term treatment, but its use is limited to doses not exceeding 20 mg per day and for no more than 12 weeks to minimize side effects[4].

Market Analysis

Current Market Position

Compazine is part of the broader antipsychotic and antiemetic drug market. While it is not a new drug, its continued use in various clinical settings ensures a stable market presence. However, the market for antipsychotics and antiemetics is evolving, with newer drugs and therapies gaining prominence.

Competitive Landscape

The market for drugs like Compazine is competitive, with other antipsychotics and antiemetics available. For instance, in the treatment of nausea and vomiting, other drugs like ondansetron and metoclopramide are widely used. In the realm of antipsychotics, newer atypical antipsychotics have become more popular due to their better side effect profiles[4].

Market Projections

General Trends

The pharmaceutical market is driven by several factors, including the increasing prevalence of chronic diseases, advances in medical technology, and government initiatives supporting drug development. However, the market for older drugs like Compazine may face challenges from newer, more innovative treatments.

Specific Projections for Compazine

Given the stable but not growing demand for Compazine, its market share is likely to remain relatively constant. The drug's sales are not expected to increase significantly, as it is largely used in niche areas where newer treatments have not yet fully penetrated. However, its established efficacy and safety profile ensure it will continue to be prescribed for specific indications.

Challenges and Limitations

Regulatory and Safety Concerns

Compazine, like other phenothiazines, comes with several safety concerns, including the risk of tardive dyskinesia, leukopenia, and agranulocytosis. These risks necessitate careful monitoring and limit its long-term use. Regulatory requirements and the need for frequent blood tests to monitor side effects can also impact its market growth[4].

Competition from Newer Therapies

The pharmaceutical market is highly competitive, and newer therapies, especially in the areas of immunotherapy and targeted therapies, are gaining traction. For example, in the non-small cell lung cancer (NSCLC) market, immunotherapies like Keytruda, Opdivo, and Tecentriq are projected to dominate the market by 2025, potentially overshadowing older drugs like Compazine in terms of innovation and market share[2].

Key Takeaways

  • Efficacy in Clinical Trials: Compazine has shown significant efficacy in treating severe headaches and non-psychotic anxiety, although its use is limited by potential side effects.
  • Market Stability: The market for Compazine is expected to remain stable but not grow significantly due to the presence of newer treatments.
  • Safety Concerns: The drug's use is limited by safety concerns such as tardive dyskinesia and blood dyscrasias.
  • Competitive Landscape: The pharmaceutical market is highly competitive, with newer therapies gaining prominence.

FAQs

What are the primary indications for Compazine?

Compazine is primarily used for the control of severe nausea and vomiting, the treatment of schizophrenia, and the short-term treatment of generalized non-psychotic anxiety[4].

What are the significant side effects of Compazine?

Significant side effects include tardive dyskinesia, leukopenia, agranulocytosis, drowsiness, dizziness, and neuroleptic malignant syndrome[4].

How does Compazine compare to newer antiemetic drugs?

Compazine is an older drug compared to newer antiemetics like ondansetron, which have better side effect profiles and are more widely used in modern clinical practice.

What are the market projections for Compazine?

The market for Compazine is expected to remain stable but not grow significantly due to the presence of newer treatments and safety concerns associated with its use.

Are there any ongoing clinical trials for new uses of Compazine?

There are no recent or ongoing clinical trials reported for new uses of Compazine, as the focus has shifted to newer and more innovative treatments.

Sources

  1. JAMA Network: Randomized Double-blind Trial of Intravenous Prochlorperazine for Severe Headaches.
  2. DrugDev: NSCLC Market - Global Drug Forecast & Market Analysis to 2025.
  3. StraitsResearch: Global Clinical Trials Market Size, Top Share, Trends, Forecast by 2033.
  4. Drugs.com: Compazine: Package Insert / Prescribing Information.
  5. GlobeNewswire: Companion Animal Pharmaceuticals Market Forecast, 2025-2030.
Last updated: 2025-01-02

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.